Arabic Arabic English English French French German German
dark

Researchers develop new generation tumor-specific pro-IL-12

Interleukin-12 (IL-12), a potent inducer of cell-mediated immunity, can stimulate the anti-tumor effector functions of the activated T and NK cells for solid tumors rejection. However, clinical administration of IL-12 has been limited because of its short half-life, low efficacy, and dose-limiting systemic toxicity. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Ask the Pediatrician: What can parents do to prevent exposure to lead?

Next Post

Boosters recommended for kids 12 and older

Related Posts
Total
0
Share